Impact of Left Atrial Appendage Exclusion on Short-Term Clinical Outcomes and Long-Term Stroke Incidence
Recruitment status was: Recruiting
Procedure: Left Atrial Appendage Ligation
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Prevention
|Official Title:||Concurrent Prophylactic Left Atrial Appendage Exclusion: A Randomized Controlled Trial|
- Incidence of Stroke [ Time Frame: 4 years ]
- Short- and Long-term biochemical parameters
- Short-term clinical outcomes (Procedural complications, hospital length of stay, etc)
|Study Start Date:||April 2007|
|Estimated Study Completion Date:||December 2011|
|Active Comparator: Left Atrial Appendage Exclusion||Procedure: Left Atrial Appendage Ligation|
|No Intervention: Control|
In patients with non-rheumatic atrial fibrillation, the left atrial appendage is the origin of at least 90% of all left atrial clots, and the resulting systemic emboli cause approximately 25% of all strokes. The stroke rate in patients with atrial fibrillation older than 75 years of age is 8.1% per year with one clinical risk factor and is 12% per year at any age in clinical trial populations with a history of prior thromboembolism. Three-year stroke rates in elderly nursing home patients not anticoagulated are in excess of 50% (Atrial Fibrillation Investigators 1994). Anticoagulation is oftentimes withheld due to the perception of excessive risk in case of a fall; even when anticoagulation is prescribed, it is well known that therapeutic levels are not always maintained.
Left atrial appendage obliteration is commonly performed in a variety of cardiac surgical operations. There have been animal studies and theoretical arguments which demonstrate the importance of the atrial appendage in its role to support cardiac output and blood pressure, and modulate thirst and hypercoagulability (Stollberger 2003); however this has been poorly studied and documented in humans in the available literature. BNP and ANP have been shown to increase proportionately with left atrial appendage dysfunction, as have von Willebrands Factor, D-Dimer, and thrombin-antithrombin III complex (Igarashi 2001).
To date, there is not a single randomized controlled trial with adequate follow-up to assess the short- and long-term clinical effectiveness of concurrent prophylactic LAA ligation. This trial will fill that void.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00486915
|Hospital San Rafael|
|Milan, MI, Italy|
|Principal Investigator:||Dave Nagpal, MD||London Health Sciences Centre|
|Principal Investigator:||Lucia Torracca, MD||Hospital San Rafael|
|Study Director:||Ottavio Alfieri, MD||Hospital San Rafael|